Get started
Author

Federico Mattiello

A broken promise: microbiome differential abundance methods do not control the false discovery rate
2017 · Stijn Hawinkel, Federico Mattiello, et al. · Briefings in Bioinformatics · 199
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
2018 · Bruce D. Cheson, Neil Chua, et al. · Journal of Clinical Oncology · 158
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL
2019 · Magdalena Klanova, Laurie H. Sehn, et al. · Blood · 127
PDF
A web application for sample size and power calculation in case-control microbiome studies
2016 · Federico Mattiello, Bie Verbist, et al. · Bioinformatics · 82
PDF
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
2021 · Lale Kostakoglu, Federico Mattiello, et al. · Haematologica · 61
PDF
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA
2021 · Lale Kostakoglu, Maurizio Martelli, et al. · Blood Advances · 58
PDF
Follicular Lymphoma Evaluation Index ( FLEX ): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy
2020 · Farheen Mir, Federico Mattiello, et al. · American Journal of Hematology · 49
PDF
Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study
2016 · Bruce D. Cheson, Marek Trněný, et al. · Blood · 37
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma
2021 · Christopher R. Bolen, Federico Mattiello, et al. · Blood · 36
PDF
Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study
2017 · Lale Kostakoglu, Maurizio Martelli, et al. · Blood · 30
An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphoma
2019 · James Normington, Jiawen Zhu, et al. · Contemporary Clinical Trials · 27
Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study
2018 · Sally F Barrington, Judith Trotman, et al. · Blood · 24
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA
2020 · Sarah C. Rutherford, Michael Herold, et al. · Blood Advances · 23
A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
2022 · Lale Kostakoglu, Federico Dalmasso, et al. · eJHaem · 20
PDF
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
2022 · Kristine Broglio, Lale Kostakoglu, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
2019 · Lale Kostakoglu, Maurizio Martelli, et al. · Blood · 3
A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial
2018 · Farheen Mir, Andrew Grigg, et al. · Blood · 3
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
2023 · Lale Kostakoglu, Maurizio Martelli, et al. · eJHaem · 2
Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma
2020 · Lale Kostakoglu, Andrew Davies, et al. · Blood · 1
A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA
2019 · Lale Kostakoglu, Paola Berchialla, et al. · Blood · 1
Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials
2018 · Sarah C. Rutherford, Michael Herold, et al. · Blood · 1
Permutation-based stochastic ordering using pairwise comparisons
2015 · Mattiello, Federico <1985> · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · 1
Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design
2019 · Donald Berry, Kristine Broglio, et al. · Blood
A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study.
2019 · Stephane Chauvie, Federico Dalmasso, et al. · Journal of Clinical Oncology
Principal bicorrelation analysis: Unraveling associations between three data sources
2015 · Federico Mattiello, Olivier Thas, et al. · Journal of Biopharmaceutical Statistics
Works count: 28
Citation count: 953
H-index: 14
I10-index: 15
Year
Topic
Type